Rigel Pharmaceuticals, Inc.
RIGL
$41.50
-$0.49-1.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 101.69M | 53.33M | 57.60M | 55.31M | 36.84M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 101.69M | 53.33M | 57.60M | 55.31M | 36.84M |
| Cost of Revenue | 4.50M | 12.85M | 11.42M | 14.21M | 2.81M |
| Gross Profit | 97.18M | 40.49M | 46.18M | 41.10M | 34.03M |
| SG&A Expenses | 29.26M | 27.72M | 29.52M | 27.04M | 28.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.58M | 40.56M | 40.94M | 41.25M | 36.39M |
| Operating Income | 61.10M | 12.77M | 16.66M | 14.06M | 447.00K |
| Income Before Tax | 59.98M | 11.51M | 15.22M | 12.42M | -1.03M |
| Income Tax Expenses | 369.00K | 65.00K | 881.00K | -- | -- |
| Earnings from Continuing Operations | 59.61M | 11.45M | 14.34M | 12.42M | -1.03M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.61M | 11.45M | 14.34M | 12.42M | -1.03M |
| EBIT | 61.10M | 12.77M | 16.66M | 14.06M | 447.00K |
| EBITDA | 61.71M | 13.38M | 17.26M | 14.67M | 1.06M |
| EPS Basic | 3.33 | 0.64 | 0.81 | 0.71 | -0.06 |
| Normalized Basic EPS | 2.10 | 0.40 | 0.54 | 0.44 | -0.04 |
| EPS Diluted | 3.28 | 0.63 | 0.80 | 0.70 | -0.06 |
| Normalized Diluted EPS | 2.06 | 0.40 | 0.53 | 0.44 | -0.04 |
| Average Basic Shares Outstanding | 17.89M | 17.81M | 17.65M | 17.60M | 17.55M |
| Average Diluted Shares Outstanding | 18.16M | 18.17M | 17.99M | 17.65M | 17.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |